Seer Sues Nanomics for Patent Infringement, Defending Core Proteomics IP
SEER is trading near its 52-week low of $1.65 (10% above the low).
Summary
Seer, Inc. has initiated a patent infringement lawsuit against Nanomics Biotechnology Co., Ltd., asserting that Nanomics' Proteonano kits and workstations infringe on several of Seer's U.S. patents covering nanoparticle protein enrichment. Brigham and Women's Hospital is also joining the suit. Seer states that its intellectual property is fundamental to its pioneering Proteograph® Product Suite and the broader field of automated, deep, unbiased proteomics, seeking monetary damages and injunctive relief. For a company of Seer's market capitalization, the defense of its core technological IP is a material event that directly impacts its competitive standing and future revenue potential. The outcome of this litigation will be a key factor for investors to monitor.
At the time of this announcement, SEER was trading at $1.82 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $102.7M. The 52-week trading range was $1.65 to $2.41. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.